{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-055806","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.744738+00:00","generated_at":"2026-06-28T10:50:26.139220+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AbCellera Q3 net loss $21.4M ($0.08/share); revenue falls to $5.5M from $9.4M","bullets":["Total revenue $5.5M, down 41% from $9.4M in Q3 2020 due to lower milestone payments and bamlanivimab royalty pause.","Net loss $21.4M ($0.08 loss per share) vs net loss $2.7M ($0.02 loss) in Q3 2020.","Cumulative program starts 69, up 35% YoY; partners increased to 35; 5 molecules in the clinic.","Acquired TetraGenetics to expand capabilities for high-value transmembrane protein targets.","Post-quarter: Eli Lilly ordered 614K additional doses of bamlanivimab with etesevimab; shipments resumed."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-055806","json":"https://secwatch.observer/filing/0001564590-21-055806.json","markdown":"https://secwatch.observer/filing/0001564590-21-055806.md","text":"https://secwatch.observer/filing/0001564590-21-055806.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000156459021055806/0001564590-21-055806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000156459021055806/abcl-8k_20211109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:50:26.139220+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}